2 results
Approved WMOPending
To show differences in uptake of Primovist between FNHs and hepatocellular adenomas on CT.
Approved WMORecruiting
The aim of this study is to evaluate the difference in the fraction of patients that have disease progression within 6 months after applying 177Lu-PSMA RLT in patients with low volume, hormone sensitive metastatic prostate cancer. Ultimately, the…